SCHEMBL177083

SCHEMBL177083

COc1cccc(N(C)S(=O)(=O)c2ccc(-c3ccc(C=O)cc3)cc2)c1

nearest known ligand 0.56

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HSD17B1 P14061 3/20 0.51
HSD17B2 P37059 3/20 0.51
CYP11B1 P15538 1/20 0.51
CYP11B2 P19099 1/20 0.51
ESR1 P03372 1/20 0.50
PGR P06401 2/20 0.49
KEAP1 Q14145 1/20 0.45
F2 P00734 1/20 0.42
L3MBTL1 Q9Y468 2/20 0.41
HTT P42858 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
ALDH1A1 P00352 2/20 0.41
LMNA P02545 1/20 0.41
POLB P06746 1/20 0.41
MCOLN3 Q8TDD5 1/20 0.41
CYP2A6 P11509 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10186896 0.81 PGR (0.70) CYP11B1CYP11B2ESR1PGRKEAP1
SCHEMBL177536 0.80 PGR (0.55) HSD17B1HSD17B2CYP11B1CYP11B2ESR1
SCHEMBL665429 0.77 TAS2R14 (0.60) HSD17B1HSD17B2ESR1PGRALDH1A1
SCHEMBL2801033 0.76 CA12 (0.67) PGRL3MBTL1HTTLMNAMCOLN3
SCHEMBL2581063 0.75 DRD1 (0.64) PGRALDH1A1CYP2A6
SCHEMBL21738397 0.74 ALDH1A1 (0.52) ESR1L3MBTL1ALDH1A1CYP2A6
SCHEMBL13577036 0.72 PGR (0.52) HSD17B1HSD17B2CYP11B1CYP11B2ESR1
SCHEMBL19019244 0.72 ALDH1A1 (0.72) PGRALDH1A1POLB
SCHEMBL23904955 0.72 GRIA2 (0.47) HSD17B1HSD17B2HTTALDH1A1LMNA
SCHEMBL13385299 0.72 ALDH1A1 (0.58) HSD17B1HSD17B2ESR1L3MBTL1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9707205-B2 S1P receptors modulators and their use thereof AKAAL PHARMA PTY LTD. (AU) 2017-07-18 US disclosed
EP-2344484-B1 S1P RECEPTORS MODULATORS AND USE THEREOF AKAAL PHARMA PTY LTD (AU) 2016-06-08 EP disclosed
US-20160038455-A1 S1P RECEPTORS MODULATORS AND THEIR USE THEREOF AKAAL PHARMA PTY LTD. (AU) 2016-02-11 US disclosed
US-9193716-B2 S1P receptors modulators and their use thereof AKAAL PHARMA PTY LTD. (AU) 2015-11-24 US disclosed
US-20140066427-A1 S1P Receptors Modulators and Their Use Thereof AKAAL PHARMA PTY LTD. (AU) 2014-03-06 US disclosed
US-8592399-B2 S1P receptors modulators and their use thereof AKAAL PHARMA PTY LTD. (AU) 2013-11-26 US disclosed
US-20110318388-A1 S1P Receptors Modulators and Their Use Thereof AKAAL PHARMA PTY LTD (AU) 2011-12-29 US disclosed
EP-2344484-A1 S1P RECEPTORS MODULATORS AND THEIR USE THEREOF Akaal Pharma Pty Ltd (AU) 2011-07-20 EP disclosed
WO-2010043000-A1 S1P RECEPTORS MODULATORS AND THEIR USE THEREOF AKAAL PHARMA PTY LTD (AU) 2010-04-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160038455-A1 S1P RECEPTORS MODULATORS AND THEIR USE THEREOF S1PR1, S1PR5, S1PR2 HSD17B1 1744/4885HSD17B2 1933/4885CYP11B1 1491/4885
US-20110318388-A1 S1P Receptors Modulators and Their Use Thereof S1PR1, S1PR5, S1PR2 HSD17B1 1744/4885HSD17B2 1933/4885CYP11B1 1491/4885
US-20140066427-A1 S1P Receptors Modulators and Their Use Thereof S1PR1, S1PR2, S1PR5 HSD17B1 3022/4885HSD17B2 3089/4885CYP11B1 3549/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.